Back to top
more

Ascendis Pharma (ASND)

(Real Time Quote from BATS)

$139.85 USD

139.85
69,998

+2.81 (2.05%)

Updated Jul 16, 2024 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

2 items in cart

View Cart/Checkout

Ascendis Pharma A/S [ASND/]

Reports for Purchase

Showing records 181 - 200 ( 303 total )

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 181

04/20/2020

Company Report

Pages: 10

Positive TC-PTH/HP Topline Eliminates SoC, Further Validates TransCon Platform

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 182

04/09/2020

Industry Report

Pages: 12

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 183

04/09/2020

Industry Report

Pages: 12

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 184

04/03/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 185

04/03/2020

Industry Report

Pages: 12

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 186

04/02/2020

Company Report

Pages: 8

4Q/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 187

04/02/2020

Company Report

Pages: 8

Q4/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 188

03/28/2020

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 189

03/09/2020

Industry Report

Pages: 5

Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 190

03/02/2020

Industry Report

Pages: 15

Monthly Check-Up- March 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 191

01/17/2020

Company Report

Pages: 8

Corporate Update and TransCon PTH Ph2 Topline Results End of March

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 192

11/20/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 193

11/19/2019

Company Report

Pages: 9

Q3 Financials; Lots of Cash - Great Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 194

11/15/2019

Company Report

Pages: 8

PaTH Forward for TransCon PTH Expands Study Enrollment; Topline Data in Q1:20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 195

10/28/2019

Company Report

Pages: 8

Initiation of Phase 3 TC-hGH Clinical Study in China

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 196

10/28/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 197

10/22/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 198

10/21/2019

Company Report

Pages: 9

Somatrogon Ph3 Non-Inferior; Despite Competition We Remain Positive on TC-hGH

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 199

09/24/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 200

09/24/2019

Company Report

Pages: 8

Thoughts on Competitor Data; We Remain Positive on TC-hGH Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party